Mailbag: Feuerstein Digs My Reporting? Print E-mail
By M.E.Garza   
Thursday, 15 October 2009 23:35

Surprise, surprise! One day after CEL-SCI (AMEX:CVM) rallies 25% due to a report here and an alert by Dow Jones, I get an e-mail from everyone's favorite biotech columnist, Adam Feuerstein, asking if I'm a paid pumper for the stock.

Not that my answer might actually matter since Adam and TheStreet.Com have already vilified and defamed our little news portal on multiple occasions (something that has not gone unnoticed, I assure you). Still, I hope it does.

Here is the nice e-mail I got from Mr. Feuerstein, who I sense is just looking out for our reputation by warning us that our content has been showing up on a certain websites (our content shows up on lots of websites since we started giving it away). It was a very nice e-mail and it reads:

"Are you aware that smallcapnetwork.com is owned by Lawrence Isen, a penny stock promoter with a long history of securities law violations. Most recently he entered into a judgment with the SEC to settle civil stock fraud charges in Dec. 2007.

Smallcapnetwork and its sister site OTC Journal, controlled by Isen, are paid to promote penny stocks. Cel-Sci has paid cash and stock for coverage on both sites.

Are you being paid by Isen to post articles to his web sites? Are you or biomedreports being paid or compensated in any way by Cel-Sci for your articles?

Please consider these on the record questions.

Thank you --

Adam Feuerstein
Senior Columnist
TheStreet.com"

My response:

Adam,

Our content and articles are syndicated all over by various networks and syndicators. We are a news portal, not a stock promoter and as such, our content appears on hundreds of news and media portals.

I was not aware of these connections regarding smallcapnetwork.com and neither I or BioMedReports are being paid by them, CVM or any other company to provide coverage.

I have never dealt with Lawrence Isen or even heard of him until now, but I appreciate you looking out for us.

I am forwarding this to our attorneys, so they becomes aware of this situation as well and can advise us if they see anything wrong with the situation.

Regards,

M.E. Garza
BioMedReports.Com

cc: Legal Dept

I'd be curious to see what some of our readers think about this one. Think Adam just wants to put the slams behind us and hug it out? Why don't we get letters like that when our stuff shows up on CBS Money Watch or Fox Business? Damn those paid pumpers!

Kidding aside, I've heard of guys who get paid to move stocks down using fear, but to move them up like that without solid news or science? Now that would be impressive.

Mind control, I say! It's got to be mind control. Quick! Get Uri Geller on the line.

Next is an e-mail from "Stock Santa Claus" which reads:

Mr. Garza,

You've been a very naughty boy and you're not going to make my list this year. How dare you pump Acorda Therapeutics in that "Acorda Bounce" article of yours the other day? It's so obvious that you're every bit the penny stock pusher that my elves tell me you are. You get nothing from me this year!

Stock Santa

My response:

So Sorry Santa. I was going to ask for something nice, but after seeing Acorda (NASDAQ:ACOR) bounce and close up nearly 50% yesterday, to $24.65 +7.91, I think I'll just buy it myself. ;)

Never trust those elves! Do your own DD. That goes for Santa and everyone else!




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter